The long-acting terminal complement C5 inhibitor, ravulizumab, appears to be effective in treating anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG) in adults, as presented in the 2023 MDA conference.
The phase 3 CHAMPION MG study is a double-blind, randomized study that compares changes in Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) total scores in adults with AChR Ab+ gMG receiving ravulizumab in comparison to a placebo control group.
Read more about myesthenia gravis therapies
The authors conducted a posthoc analysis of the CHAMPION MG study in order to assess the response to ravulizumab in different muscle domains (ocular, bulbar, limb, and respiratory). The posthoc analysis was based on a mixed model for repeated measures that aimed to calculate the mean changes from baseline to week 26 in MG-ADL and QMG scores.
Moreover, the results of the study showed that ravulizumab treatment led to greater improvements in ocular and respiratory muscle domains on the MG-ADL scale and in ocular and limb domains on the QMG scale than the placebo group.
The least-squares mean MG-ADL score changes from baseline to week 26 showed greater improvements for ravulizumab than placebo in ocular and respiratory domains. Similar results were observed for the bulbar and limb domains. For QMG, greater improvements for ravulizumab than placebo were seen in ocular and limb domains. There was no difference in the bulbar and respiratory domains.
According to these results, ravulizumab appears to be effective in treating anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG) in adults, particularly in ocular and respiratory muscle domains on the MG-ADL scale and in ocular and limb domains on the QMG scale. The authors of this study support the use of ravulizumab in the treatment of AChR Ab+ gMG.
“Ravulizumab treatment resulted in greater improvements compared with placebo in ocular and respiratory muscle domains on the MG-ADL scale and in ocular and limb domains on the QMG scale,” the authors concluded.
Reference
Tahseen M, Renato M, Shahram A, et al. Ravulizumab in adults with generalized myasthenia gravis: a post-hoc analysis of the phase 3 CHAMPION MG study by muscle domain. Poster presented at: 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference; March 19-22, 2023; Dallas, TX
